major depressive disorder

Alto’s Neuropsychiatric Platform Scores Third Mid-Stage Win
BioSpace
Tue, 12/5/23 - 09:55 am
Alto Neuroscience
ALTO-300
major depressive disorder
clinical trials
Xenon Looks to Raise Cash for MDD Program with $300M Public Offering
BioSpace
Thu, 11/30/23 - 11:15 pm
Xenon
major depressive disorder
stock offering
Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry
BioSpace
Fri, 11/10/23 - 10:14 am
Neurocrine
neuropsychiatric
clinical trials
focal onset seizures
major depressive disorder
NBI-921352
NBI-1065846
Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline
Fierce Biotech
Tue, 10/10/23 - 11:36 am
Novartis
Cadent Therapeutics
major depressive disorder
MIJ821
Exxua Charts a New Path in Depression Treatment Following FDA Nod
Xtalks
Thu, 09/28/23 - 11:38 pm
Fabre-Kramer Pharmaceuticals
FDA
Exxua
major depressive disorder
depression
Biomed reports data from trial of MDD therapy
Clinical Trials Arena
Wed, 08/16/23 - 09:58 am
BioMed
NA-831
major depressive disorder
clinical trials
Biogen, Sage's postpartum depression approval overshadowed by larger rejection
Fierce Pharma
Mon, 08/7/23 - 12:01 pm
SAGE Therapeutics
Biogen
FDA
Zurzuvae
postpartum depression
major depressive disorder
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Sun, 08/6/23 - 09:39 pm
Biogen
SAGE Therapeutics
FDA
Zurzuvae
postpartum depression
major depressive disorder
zuranolone
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
Mon, 07/31/23 - 10:05 am
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
Sat, 07/29/23 - 10:45 pm
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder
Genetic Engineering News
Fri, 04/14/23 - 10:09 am
MindMed
clinical trials
lysergide
LSD
major depressive disorder
Intra-Cellular reports positive Phase III trial of Caplyta in MDD and bipolar depression
Clinical Trials Arena
Wed, 03/29/23 - 09:40 am
Intra-Cellular Therapies
clinical trials
Caplyta
major depressive disorder
bipolar disorder
Relmada Looks to Rebound with New Protocol After Two Phase III Flops
BioSpace
Mon, 03/27/23 - 10:05 am
Relmada Therapeutics
REL-1017
major depressive disorder
FDA says no adcomm planned for Biogen, Sage's depression drug
Seeking Alpha
Wed, 03/8/23 - 09:47 pm
Biogen
SAGE Therapeutics
FDA
zuranolone
major depressive disorder
postpartum depression
Biogen, Sage Get FDA Priority Review of Zuranolone
Marketwatch
Mon, 02/6/23 - 10:47 am
Biogen
SAGE Therapeutics
FDA
zuranolone
priority review
postpartum depression
major depressive disorder
Small Pharma’s depressive disorder therapy trial meets primary goal
Clinical Trials Arena
Thu, 01/26/23 - 10:36 am
Small Pharma
clinical trials
SPL026
major depressive disorder
Relmada’s MDD Drug Misses Endpoint, Marred by “Paradoxical Results”
BioSpace
Thu, 10/13/22 - 11:45 pm
Relmada
REL-1017
major depressive disorder
clinical trials
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
Endpoints
Mon, 09/19/22 - 09:53 pm
SAGE Therapeutics
Biogen
major depressive disorder
zuranolone
Psychedelics startup nets more than $10M in seed funding as it looks to make a splash
Endpoints
Tue, 08/23/22 - 10:25 am
Freedom Biosciences
major depressive disorder
psychedelics
ketamine
FREE001

Pages